Scancell Holdings plc (SCLP.L), a clinical stage biopharmaceutical company, Tuesday said it has signed a deal with PharmaJet for the supply of Stratis intramuscular needle-free injection system. Scancell uses this for delivery of its SCIB1/iSCIB1+ cancer vaccine for advanced melanoma, which is in Phase 2 study.
"Delivering SCIB1/iSCIB1+ intramuscularly via Stratis has shown effective uptake of the DNA vaccine and has the potential to provide clinical benefit to patients with advanced/metastatic melanoma by allowing native cellular machinery to express the target antigen and induce a potent anti-tumour response," Scancell said in a statement.
Data from the Phase 2 SCOPE study of SCIB1 and iSCIB1+ are expected in the fourth quarter of 2024 and first quarter of 2025 respectively. A Phase 2/3 registrational study is planned for 2025.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.